JP2024508749A - クローンｔ細胞増殖を処置するための方法および材料 - Google Patents

クローンｔ細胞増殖を処置するための方法および材料 Download PDF

Info

Publication number
JP2024508749A
JP2024508749A JP2023549562A JP2023549562A JP2024508749A JP 2024508749 A JP2024508749 A JP 2024508749A JP 2023549562 A JP2023549562 A JP 2023549562A JP 2023549562 A JP2023549562 A JP 2023549562A JP 2024508749 A JP2024508749 A JP 2024508749A
Authority
JP
Japan
Prior art keywords
polypeptide
binding
antigen
binding domain
trbc
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023549562A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024508749A5 (enExample
Inventor
マイケル エス． ワン
ケネス ダブリュ． キンズラー
ブライアン ジェイ． モグ
ニコラス パパドポウロス
アンドリュー パードール
スマン ポール
バート フォーゲルシュタイン
シビン チョウ
Original Assignee
ザ・ジョンズ・ホプキンス・ユニバーシティー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ザ・ジョンズ・ホプキンス・ユニバーシティー filed Critical ザ・ジョンズ・ホプキンス・ユニバーシティー
Publication of JP2024508749A publication Critical patent/JP2024508749A/ja
Publication of JP2024508749A5 publication Critical patent/JP2024508749A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3061—Blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/626—Diabody or triabody
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2023549562A 2021-02-17 2022-02-15 クローンｔ細胞増殖を処置するための方法および材料 Pending JP2024508749A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163150232P 2021-02-17 2021-02-17
US63/150,232 2021-02-17
PCT/US2022/016423 WO2022177889A1 (en) 2021-02-17 2022-02-15 Methods and materials for treating clonal t cell expansions

Publications (2)

Publication Number Publication Date
JP2024508749A true JP2024508749A (ja) 2024-02-28
JP2024508749A5 JP2024508749A5 (enExample) 2025-02-17

Family

ID=80595091

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023549562A Pending JP2024508749A (ja) 2021-02-17 2022-02-15 クローンｔ細胞増殖を処置するための方法および材料

Country Status (7)

Country Link
US (1) US20240124608A1 (enExample)
EP (1) EP4294841A1 (enExample)
JP (1) JP2024508749A (enExample)
CN (1) CN117561277A (enExample)
AU (1) AU2022222679A1 (enExample)
CA (1) CA3211203A1 (enExample)
WO (1) WO2022177889A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025220689A1 (ja) * 2024-04-17 2025-10-23 Ｍｅｉｊｉ Ｓｅｉｋａファルマ株式会社 Ｔ細胞機能不全のｔ細胞性腫瘍患者に有効な二重特異性抗体

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120076829A (zh) 2022-10-18 2025-05-30 明治制果药业株式会社 T细胞肿瘤的治疗剂
JP2026524330A (ja) * 2023-06-28 2026-07-22 ザ・ジョンズ・ホプキンス・ユニバーシティ Ｔｒｂｃ標的化抗体薬物複合体

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020527027A (ja) * 2017-06-09 2020-09-03 オートラス リミテッド 抗ｔｒｂｃ１抗原結合ドメイン

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2744046C2 (ru) * 2014-03-05 2021-03-02 Отолус Лимитед ХИМЕРНЫЙ АНТИГЕННЫЙ РЕЦЕПТОР (CAR) С АНТИГЕНСВЯЗЫВАЮЩИМИ ДОМЕНАМИ К КОНСТАНТНОЙ ОБЛАСТИ β Т-КЛЕТОЧНОГО РЕЦЕПТОРА
GB201817172D0 (en) * 2018-10-22 2018-12-05 Autolus Ltd Antibody
GB201817822D0 (en) * 2018-10-31 2018-12-19 Autolus Ltd Binding domain

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020527027A (ja) * 2017-06-09 2020-09-03 オートラス リミテッド 抗ｔｒｂｃ１抗原結合ドメイン

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
PROTEIN ENGINEERING DESIGN AND SELECTION, vol. 19, no. 8, JPN6026003724, 2006, pages 359 - 367, ISSN: 0005785640 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025220689A1 (ja) * 2024-04-17 2025-10-23 Ｍｅｉｊｉ Ｓｅｉｋａファルマ株式会社 Ｔ細胞機能不全のｔ細胞性腫瘍患者に有効な二重特異性抗体

Also Published As

Publication number Publication date
AU2022222679A1 (en) 2023-09-07
WO2022177889A1 (en) 2022-08-25
CN117561277A (zh) 2024-02-13
US20240124608A1 (en) 2024-04-18
EP4294841A1 (en) 2023-12-27
CA3211203A1 (en) 2022-08-25

Similar Documents

Publication Publication Date Title
US20240218077A1 (en) Anti-cd47 agent-based treatment of cd20-positive cancer
AU2018250336B2 (en) Engineered cells expressing prostate-specific membrane antigen (PSMA) or a modified form thereof and related methods
JP2022116283A (ja) 三重特異性タンパク質と使用方法
CN107847587A (zh) Cd30×cd16抗体与pd‑1拮抗剂的联合药物用于治疗
US20240124608A1 (en) Methods and materials for treating clonal t cell expansions
CN115920007A (zh) 组合
CN105579058A (zh) Cd38激动剂的医学用途
CN101172158A (zh) 抗cd26单克隆抗体作为对与表达cd26的细胞相关疾病的治疗
JP2022532490A (ja) 癌の治療における有効性の増強のためのｐｄ－１阻害剤とｌａｇ－３阻害剤の組み合わせ
EP3691661A1 (en) Combination for t-cell immunotherapy and use thereof
CN112292140B (zh) 靶向cd37和cd19的嵌合抗原受体
EP3268387A1 (en) Compositions and methods for enhancing the efficacy of cancer therapy
US20240002541A1 (en) Methods and materials for treating t cell cancers
JP2024513506A (ja) がんの治療のためのＣＤ４７／ＳＩＲＰα結合及びＮＥＤＤ８活性化酵素Ｅ１調節サブユニットの共阻害
KR20200068746A (ko) Il8의 emt 경로 차단 및 암 줄기 세포 극복(il8 bloking emt pathway and overcoming cancer stem cells)
US20230134725A1 (en) Fusion Protein Extensions
KR20210143896A (ko) 암 요법에 사용하기 위한 세마포린-4d 길항제
KR20250029015A (ko) 다발성 골수종의 치료를 위한, 다른 제제와 조합된 이사툭시맙의 용도
US20230241237A1 (en) Immune Cell Redirecting Compositions and Therapeutic Uses Thereof
AU2007209787B2 (en) Anti-CD26 monoclonal antibodies as therapy for diseases associated with cells expressing CD26
WO2026060097A1 (en) Methods and materials for targeting c-c chemokine receptor-like 2 (ccrl2)
HK40119904A (en) Methods of administering natural killer cells comprising an anti-human epidermal growth factor receptor 2 (her2) chimeric antigen receptor (car)
CN118201614A (zh) 用于癌症治疗的tlr7激动剂及组合

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250206

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250206

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20260116

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260202

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20260430

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20260716

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260731

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20260731